Studies have revealed a significant upregulation of lncRNA-MEG3 and concomitant downregulation of miR-23c in serum samples from patients with DN, renal tissues, and HG-treated human MCs (HMCs), with a negative correlation observed between these two molecules, silencing of lncRNA-MEG3 suppressed HG-induced HMC proliferation and induced G0–G1 phase cell cycle arrest, while reducing the expression levels of fibrotic markers FN and Col-IV, inflammatory cytokines IL-6 and TNF-α, and mesenchymal marker N-cadherin. The gene discussed is CDH2; the disease is liver dysplastic nodule.